News

StemBioSys CEO: Company has room to grow in San Antonio

Bob Hutchens is CEO of StemBioSys Inc. CARLOS JAVIER SANCHEZ | SABJ By W. Scott Bailey – Senior ...

SA researchers exploring use of re-purposed cancer drugs to combat deadly TB

Texas Biomedical Research Institute President and CEO Dr. Larry Schlesinger, right, with Eusondia Arnett, ...

News
CTRC patients enrolled in GenSpera cancer drug trial San Antonio Business Journal
March 28, 2011

The Cancer Therapy & Research Center has enrolled its first patient in a Phase 1 clinical trial using GenSpera's new G-202 chemotherapeutic agent.

Cancer drug company GenSpera Inc. said Monday that the first patient received a dosage of the company's experimental drug, G-202, at the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio.

San Antonio-based GenSpera (OTCBB: GNSZ) is conducting Phase 1 clinical trials at the University of Wisconsin Carbone Cancer Center and now the CTRC.

 

Stay informed. Subscribe to BioMed SA news alerts.